Purple Biotech (PPBT) Assets Average (2014 - 2026)

Purple Biotech (PPBT) has 7 years of Assets Average data on file, last reported at $16.0 million in Q1 2026.

• Quarterly Assets Average changed N/A year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (changed N/A YoY) and the FY2025 annual result came in at $27.3 million, down 32.86% from the prior year.
• Assets Average eased to $16.0 million in Q1 2026 per PPBT's latest filing, from $40.7 million in the prior quarter.
• Across five years, Assets Average topped out at $62.4 million in Q4 2022 and bottomed at $16.0 million in Q1 2026.
• The 4-year median for Assets Average is $45.1 million (2023), against an average of $42.1 million.
• The widest annual swing landed in 2023, when Assets Average retreated 20.75%; it then dropped 17.78% in 2024.
• Tracing PPBT's Assets Average over 4 years: stood at $62.4 million in 2022, then dropped by 20.75% to $49.5 million in 2023, then slipped by 17.78% to $40.7 million in 2024, then sank by 60.67% to $16.0 million in 2026.
• Per Business Quant, the three latest PPBT Assets Average figures stand at $16.0 million (Q1 2026), $40.7 million (Q4 2024), and $49.5 million (Q4 2023).

Peer Comparison